+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Leukemia Therapeutics Market - Global Forecast 2026-2032- Product Image
Leukemia Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Leukemia Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896743
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Leukemia Therapeutics Market is projected to reach USD 19.48 Billion in 2026. It is expected to continue growing at a CAGR of 7.18%, reaching USD 29.63 Billion by 2032.

Leukemia therapeutics are being reshaped by precision medicine, measurable residual disease (MRD)-guided care, and expanding use of targeted agents across acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).

Market momentum is supported by validated molecular targets, broader genomic testing, and treatment standards that increasingly combine tyrosine kinase inhibitors, BCL-2 inhibition, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR-T cell therapies. The commercial opportunity is strongest where payers, cancer centers, and manufacturers align evidence generation with durable remission, toxicity reduction, outpatient feasibility, and real-world value.

Transformative Shifts in Leukemia Care

The leukemia treatment landscape has shifted from broadly cytotoxic chemotherapy toward biologically defined, patient-specific regimens. In CML, BCR-ABL tyrosine kinase inhibitors transformed survival and created a benchmark for chronic cancer control. In CLL, BTK inhibitors and BCL-2-based fixed-duration regimens have reduced reliance on chemoimmunotherapy. In AML and ALL, genomic stratification, MRD testing, and immunotherapies are changing induction, consolidation, maintenance, and relapse strategies.

Transformative shifts also include earlier-line use of targeted combinations, expanding transplant alternatives, and growing clinical interest in time-limited therapy. Regulators and clinicians are emphasizing endpoints such as event-free survival, MRD negativity, complete remission with incomplete hematologic recovery, overall survival, and patient-reported outcomes. These changes favor organizations with differentiated mechanisms, companion diagnostics, scalable manufacturing, and evidence packages that address both efficacy and health-system affordability.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative impact across leukemia therapeutics by accelerating target discovery, optimizing trial design, improving image and flow-cytometry interpretation, and supporting risk prediction from multi-omic and electronic health record data. AI-enabled models are increasingly used to identify molecular subgroups, predict relapse, and match patients to trials, although clinical adoption depends on prospective validation, explainability, and regulatory-grade performance.

The most immediate commercial value is in operational efficiency: faster site selection, better patient screening, adaptive trial analytics, pharmacovigilance signal detection, and real-world evidence generation. AI can also improve manufacturing quality control for cell therapies and support dose optimization for combination regimens. Leaders must address bias, data privacy, interoperability, and medical oversight because AI tools in oncology influence high-risk treatment decisions and must comply with evolving FDA, EMA, and data-protection expectations.

Key Regional Insights for Leukemia Therapeutics

North America remains a leading region for leukemia therapeutics because of high clinical-trial density, rapid FDA oncology review pathways, strong biomarker adoption, and broad access to academic cancer networks. The United States drives uptake of novel CLL, AML, ALL, and CML therapies, while Canada benefits from centralized health technology assessment, provincial oncology programs, and guideline-based cancer care.

Europe combines advanced hematology infrastructure with pricing and reimbursement scrutiny, making comparative value evidence essential across major national health systems. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia scale genomic testing, domestic clinical development, and oncology reimbursement for targeted leukemia therapies. Latin America shows rising demand, especially in Brazil and Mexico, but access gaps remain due to uneven diagnostic capacity and public-sector budget limitations. The Middle East is investing in tertiary oncology centers and specialty care, particularly in Gulf states, where referral networks and high-acuity hospitals support advanced therapies. Africa faces the highest constraints in diagnostics, specialist capacity, transplant availability, and drug affordability, making partnerships, training, and essential-medicine access critical for improving leukemia outcomes.

Key Group Insights Across Economic Blocs

ASEAN markets are improving leukemia care through expanding universal health coverage, regional cancer plans, and private-sector oncology investment, although access to molecular diagnostics, hematopathology, transplant services, and advanced immunotherapies varies significantly by country. GCC health systems are prioritizing specialty oncology, domestic clinical capacity, referral-center development, and medical tourism, supporting demand for premium leukemia therapies when reimbursement pathways and treatment protocols are clearly defined.

The European Union is influential through centralized EMA review, joint clinical assessment under evolving health technology frameworks, rare-disease policy alignment, and strong cross-border hematology research networks. BRICS countries represent a large patient base and growing local manufacturing capacity, with China and India especially important for trial recruitment, biosimilar competition, and cost-sensitive access strategies. G7 markets remain the highest-value innovation cluster due to mature reimbursement systems, public research funding, comprehensive cancer centers, and specialty care infrastructure. NATO overlap is commercially relevant because many member countries share advanced procurement standards, supply-chain resilience priorities, and health-system security planning that influence continuity of oncology medicine supply.

Key Country Insights in Leukemia Therapeutics

The United States leads in leukemia drug launches, CAR-T adoption, and investigator-sponsored research, supported by FDA oncology programs and National Cancer Institute networks. Canada emphasizes cost-effectiveness, clinical benefit, and equitable provincial access. Mexico and Brazil are important Latin American markets where public reimbursement, private oncology care, diagnostic availability, and biosimilar penetration shape uptake of leukemia therapeutics.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong hematology expertise with formal health technology assessment, centralized or regional reimbursement review, and guideline-driven care, while Russia maintains demand but faces supply-chain and geopolitical constraints. China has become a major engine for leukemia trials, domestic BTK inhibitor development, CAR-T research, and broader oncology reimbursement reform. India offers large patient volume and expanding specialty hospitals but remains highly price-sensitive, with access influenced by out-of-pocket spending and public insurance expansion. Japan and South Korea provide advanced diagnostics, aging-population demand, strong academic hematology networks, and innovation-friendly regulatory pathways. Australia supports early adoption through clinical trials, public reimbursement review, and strong hematology cooperative groups.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-defined indications, MRD-integrated development plans, and differentiated safety profiles that enable outpatient use and longer treatment adherence. Clinical programs should include diverse populations, elderly and unfit patients, and real-world comparators that reflect current standards of care rather than legacy chemotherapy alone.

Manufacturers should build access strategies early by aligning price, evidence, and outcomes with payer expectations. Companion diagnostics, decentralized trial capabilities, and partnerships with cancer centers can improve patient identification and enrollment. Developers of cell and gene therapies should invest in manufacturing reliability, vein-to-vein time reduction, toxicity management education, and regional treatment networks. Across all modalities, AI governance, pharmacovigilance readiness, and supply-chain resilience are now strategic requirements rather than support functions.

Research Methodology

This executive summary is grounded in secondary research from authoritative public sources, including global cancer incidence databases, regulatory agency communications, peer-reviewed hematology literature, clinical-practice guidelines, and health technology assessment frameworks. Core references include organizations such as the World Health Organization, International Agency for Research on Cancer, U.S. FDA, European Medicines Agency, National Cancer Institute, and major hematology societies.

Insights are synthesized through market segmentation by leukemia subtype, therapy class, mechanism of action, line of therapy, region, and access environment. The analysis emphasizes verified clinical and commercial trends, including approved therapies, guideline-supported treatment evolution, trial activity, diagnostic adoption, reimbursement dynamics, and regional infrastructure. No unsupported market-size, market-share, or forecasting claims are used; conclusions reflect evidence-backed patterns and observable industry developments.

Conclusion

Leukemia therapeutics are entering a new phase in which clinical differentiation depends on molecular precision, durable remission, manageable toxicity, and credible real-world value. Targeted agents, immunotherapies, and cellular therapies are improving outcomes across major leukemia subtypes, but access remains uneven across regions and income levels.

The next competitive advantage will come from integrating diagnostics, data science, manufacturing excellence, and payer-ready evidence into one coordinated strategy. Organizations that can demonstrate survival benefit, MRD-driven depth of response, quality-of-life improvement, and scalable delivery will be best positioned in the global leukemia therapeutics market. As AI and precision oncology mature, industry leaders must balance speed of innovation with rigorous validation, affordability, and equitable patient access.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Leukemia Therapeutics Market, by Type
7.1. Introduction
7.2. Acute Lymphoblastic Leukemia (ALL)
7.3. Acute Myeloid Leukemia (AML)
7.4. Chronic Lymphocytic Leukemia (CLL)
7.5. Chronic Myeloid Leukemia (CML)
7.6. Hairy Cell Leukemia (HCL)
7.7. Juvenile Myelomonocytic Leukemia (JMML)
7.8. T-cell Prolymphocytic Leukemia (T-PLL)
8. Leukemia Therapeutics Market, by Mechanism of Action
8.1. Introduction
8.2. Immunotherapy
8.2.1. Bispecific T-cell Engagers (BiTEs)
8.2.2. CAR-T Cell Therapy
8.2.3. Immune Checkpoint Inhibitors
8.2.4. Monoclonal Antibodies
8.3. Targeted Therapy
8.3.1. BCL-2 Inhibitors
8.3.2. CDK Inhibitors
8.3.3. FLT3 Inhibitors
8.3.4. IDH1/IDH2 Inhibitors
8.3.5. PI3K Inhibitors
8.3.6. Tyrosine Kinase Inhibitors (TKIs)
9. Leukemia Therapeutics Market, by Line of Therapy
9.1. Introduction
9.2. First-Line Therapy
9.3. Second-Line / Salvage Therapy
10. Leukemia Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Intrathecal
10.3. Intravenous (IV)
10.4. Oral
10.5. Subcutaneous (SC)
11. Leukemia Therapeutics Market, by Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Leukemia Therapeutics Market, by End-User
12.1. Introduction
12.2. Academic Research Institutes
12.3. Cancer Treatment Centers
12.4. Hospitals
12.5. Specialty Clinics
13. Leukemia Therapeutics Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Leukemia Therapeutics Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Leukemia Therapeutics Market, by Country
15.1. United States
15.2. Germany
15.3. China
15.4. United Kingdom
15.5. India
15.6. Japan
15.7. Russia
15.8. Brazil
15.9. Canada
15.10. Italy
15.11. Mexico
15.12. France
15.13. Spain
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Amgen Inc.
17.3. AstraZeneca PLC
17.4. Biogen Inc.
17.5. Celgene Corporation by Bristol Myers Squibb Company
17.6. Eisai Co., Ltd.
17.7. Eli Lilly and Company
17.8. EUSA Pharma (UK) Limited
17.9. F. Hoffmann-La Roche Ltd.
17.10. Gilead Sciences, Inc.
17.11. GlaxoSmithKline PLC
17.12. Incyte Corporation
17.13. Johnson & Johnson Services, Inc.
17.14. Novartis AG
17.15. Pfizer Inc.
17.16. Servier Pharmaceuticals LLC
17.17. Takeda Pharmaceutical Company Limited
17.18. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL LEUKEMIA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL LEUKEMIA THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL LEUKEMIA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL LEUKEMIA THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 15. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CHRONIC MYELOID LEUKEMIA (CML) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CHRONIC MYELOID LEUKEMIA (CML) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CHRONIC MYELOID LEUKEMIA (CML) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL HAIRY CELL LEUKEMIA (HCL) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL HAIRY CELL LEUKEMIA (HCL) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL HAIRY CELL LEUKEMIA (HCL) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL BISPECIFIC T-CELL ENGAGERS (BITES) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL BISPECIFIC T-CELL ENGAGERS (BITES) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL BISPECIFIC T-CELL ENGAGERS (BITES) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL BCL-2 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL BCL-2 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BCL-2 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CDK INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL CDK INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL CDK INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL IDH1/IDH2 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL IDH1/IDH2 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL IDH1/IDH2 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PI3K INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PI3K INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PI3K INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SECOND-LINE / SALVAGE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SECOND-LINE / SALVAGE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL SECOND-LINE / SALVAGE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SUBCUTANEOUS (SC) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SUBCUTANEOUS (SC) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SUBCUTANEOUS (SC) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL CANCER TREATMENT CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL CANCER TREATMENT CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL CANCER TREATMENT CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 133. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 135. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 136. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 137. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 138. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 139. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 140. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 141. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 151. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 153. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 154. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 155. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 156. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 157. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 158. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 159. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 163. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 164. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 165. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 166. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 167. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 168. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 169. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 170. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 172. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 173. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 174. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 175. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 176. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 177. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 178. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 188. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 190. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 191. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 192. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 193. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 194. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 195. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 196. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 197. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 199. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 200. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 201. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 202. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 203. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 204. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 205. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 206. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 207. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 208. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 209. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 210. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 211. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 212. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 213. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 214. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 215. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 216. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 218. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 219. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 220. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 221. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 222. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 223. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 224. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 225. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 227. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 228. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 229. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 230. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 231. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 232. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 233. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 234. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 235. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 236. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 237. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 238. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 239. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 240. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 242. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 243. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 252. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 254. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 255. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 256. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 257. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 258. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 259. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 260. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 261. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 262. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 263. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 264. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 265. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 266. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 267. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 268. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 269. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 270. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 272. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 273. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 274. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 275. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 276. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 277. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 278. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 279. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 281. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 282. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 283. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 284. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 285. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 286. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 287. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 288. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 290. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 291. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 292. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 293. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 294. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 295. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 296. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 297. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 298. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 299. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 300. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 301. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 302. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 303. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 304. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 305. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 306. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 308. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 309. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 310. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 311. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 312. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 313. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 314. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 315. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 317. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 318. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 319. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 320. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 321. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 322. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 323. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 324. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 326. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 327. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 328. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 329. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 330. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 331. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 332. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 333. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 334. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 335. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 336. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 337. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 338. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 339. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 340. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 341. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 342. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 343. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 344. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 345. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 346. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 347. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 348. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 349. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 350. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 351. GLOBAL LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 352. GLOBAL LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Celgene Corporation by Bristol Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • EUSA Pharma (UK) Limited
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Servier Pharmaceuticals LLC
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 19.48 Billion
Forecasted Market Value ( USD ) by 2032 $ 29.63 Billion
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

U.S. Leukemia Therapeutics Market Size, Share & Trends Analysis Report by Type (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)), Treatment, Distribution Channels with Growth Forecasts, 2025-2033 - Product Image

U.S. Leukemia Therapeutics Market Size, Share & Trends Analysis Report by Type (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)), Treatment, Distribution Channels with Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • United States
From
North America Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and Chemotherapy), By Distribution Channel, By Type, By Country and Growth Forecast, 2023 - 2029 - Product Image

North America Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and Chemotherapy), By Distribution Channel, By Type, By Country and Growth Forecast, 2023 - 2029

  • Report
  • 96 Pages
  • North America
From
Leukemia Therapeutics - Global Strategic Business Report - Product Image

Leukemia Therapeutics - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Chronic Lymphocytic Leukemia Therapeutics Market - Global Forecast 2026-2032 - Product Image

Chronic Lymphocytic Leukemia Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Hairy Cell Leukemia Therapeutics Market - Global Forecast 2026-2032 - Product Image

Hairy Cell Leukemia Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From

About the Leukemia Drugs Market

The Leukemia Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat leukemia, a type of cancer of the blood and bone marrow. These drugs are used to reduce the number of cancer cells in the body, and to prevent the spread of the disease. Commonly used drugs include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is a type of drug that works by killing cancer cells. Targeted therapy is a type of drug that works by targeting specific molecules in cancer cells, and immunotherapy is a type of drug that works by stimulating the body's immune system to fight cancer cells. The Leukemia Drugs market is highly competitive, with many companies competing for market share. Some of the major players in the market include Novartis, Pfizer, Bristol-Myers Squibb, Celgene, and Amgen. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.